Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 5 - Drugs for disorders of the endocrine system
Patents for A61P 5 - Drugs for disorders of the endocrine system (28,908)
12/2000
12/28/2000WO2000078750A1 New pharmaceutically active compounds
12/28/2000WO2000078726A1 Imidazoline derivatives for the treatment of diabetes, especially type ii diabetes
12/28/2000WO2000078325A1 Synergistic compositions containing lycopene and silymarin for treatment of liver disease
12/28/2000WO2000078321A1 Agent for regulating iodine exchange or for preventing iodine-deficit conditions
12/28/2000WO2000078319A1 Dihydropyrazine derivatives as npy antagonists
12/28/2000WO2000054780A3 Corticosteroid formulation
12/28/2000WO2000043495A3 33 human secreted proteins
12/28/2000DE19929715A1 New 11-beta-long chain substituted estratriene derivatives, are antiestrogens or tissue-selective partial estrogens useful e.g. for treating hormone-dependent cancer or osteoporosis
12/28/2000CA2377698A1 Dihydropyrazine derivatives as npy antagonists
12/28/2000CA2376081A1 Cysteinyl protease inhibitors
12/28/2000CA2375781A1 Compositions and methods for increasing cholesterol efflux and raising hdl using atp binding cassette transporter protein abci
12/28/2000CA2375493A1 Human transport proteins
12/28/2000CA2375407A1 Rna metabolism proteins
12/28/2000CA2375207A1 Peptide having preptin functionality
12/28/2000CA2373497A1 Chromeno[4,3,2-de]isoquinolines as potent dopamine receptor ligands
12/28/2000CA2345350A1 Agent for regulating iodine exchange or for preventing iodine-deficit conditions
12/27/2000EP1062240A1 N-terminally modified glp-1 derivatives
12/27/2000EP1062229A1 Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
12/27/2000EP1062218A1 MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases)
12/27/2000EP1062215A1 Antagonists of gonadotropin releasing hormone
12/27/2000EP1062210A1 1,2-diazepane derivatives as interleukin-1beta converting enzyme inhibitors
12/27/2000EP1062199A1 Modulators of protein tyrosine phosphatases (ptpases)
12/27/2000CN1059902C Estrogen excitant/antagonist
12/26/2000US6166077 Use of L-acetylcarnitine, L-isovalerylcarnitine, L-propionylcarnitine for increasing the levels of IGF-1
12/26/2000US6166075 A 3,4-diphenylbicyclo(4.3.0)nonyl compound
12/26/2000US6166043 Insulin sensitivity enhancer such as pioglitazone in combination with a biguanide such as metformin
12/26/2000US6166042 Pharmaceutical composition
12/21/2000WO2000077256A1 48 human secreted proteins
12/21/2000WO2000077237A1 49 human secreted proteins
12/21/2000WO2000077233A2 Complement-resistant non-mammalian dna viruses and uses thereof
12/21/2000WO2000077022A1 50 human secreted proteins
12/21/2000WO2000077011A1 Organosilyl compounds having nuclear hormone receptor modulating activity
12/21/2000WO2000076556A2 High dose radionuclide complexes for bone marrow suppression
12/21/2000WO2000076531A1 47 human secreted proteins
12/21/2000WO2000076522A1 Administration of non-oral androgenic steroids to women
12/21/2000WO2000076503A1 1-(4-sulfamylaryl)-3-substituted-5-aryl-2-pyrazolines as inhibitors of cyclooxygenase-2
12/21/2000WO2000052049A3 A method for purifying human growth hormone
12/21/2000WO2000047580A3 Phenyl urea and phenyl thiourea derivatives
12/21/2000WO2000045791A3 Method for controlling liposome size
12/21/2000WO2000044710A3 Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
12/21/2000CA2391364A1 47 human secreted proteins
12/21/2000CA2382748A1 50 human secreted proteins
12/21/2000CA2382735A1 49 human secreted proteins
12/21/2000CA2382185A1 48 human secreted proteins
12/21/2000CA2377153A1 1-(4-sulfamylaryl)-3-substituted-5-aryl-2-pyrazolines as inhibitors of cyclooxygenase-2
12/21/2000CA2375825A1 Complement-resistant non-mammalian dna viruses and uses thereof
12/21/2000CA2375797A1 Organosilyl compounds having nuclear hormone receptor modulating activity
12/20/2000EP1060191A1 Derivatives of glp-1 analogs
12/20/2000EP1060190A1 New salt forms of (2e)- 5-amino-5- methylhex-2- enoic acid n-methyl-n-((1r)-1-(n- methyl-n-((1r)-1-(methylcarbamoyl)-2- phenylethyl)carbamoyl)-2- (2-naphtyl)ethyl)amide
12/20/2000EP1060188A1 Cholenic acid amides and pharmaceutical compositions thereof
12/20/2000EP1060186A1 20-keto-11beta-arylsteroids and their derivatives having agonist or antagonist hormonal properties
12/20/2000EP0842148B1 Benzenesulphonamide derivatives, preparation thereof and therapeutical uses thereof
12/20/2000CN1277612A Nitrogen-containing heterocyclic compounds, their production and use
12/20/2000CN1277611A 3-substituted tetrahydropyridopyrimidinone derivatives, method for producing the same, and their use
12/20/2000CN1277605A Arylpyridazinones as prostaglandin endoperoxide H synthase biosynthesis inhibitors
12/20/2000CN1277033A Medicine for treating benign goiter
12/19/2000US6162813 Antagonists of gonadotropin releasing hormone
12/19/2000US6162790 Oligopeptides
12/19/2000CA2050291C Combination therapy for the treatment of estrogen sensitive diseases
12/14/2000WO2000075186A1 Neuromedin b and somatostatin receptor agonists
12/14/2000WO2000075139A2 Benzothiazinone and benzoxazinone compounds
12/14/2000WO2000074736A1 Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same
12/14/2000WO2000074724A2 Conjugates comprising cytokines and nucleic acids for treating proliferating cells
12/14/2000WO2000074718A1 Immunotherapy of autoimmune disorders using antibodies which target b-cells
12/14/2000WO2000074706A1 Therapeutic use of an inhibitor of a hedgehog or a hedgehog-related signalling pathway
12/14/2000WO2000074702A1 Compositions for the treatment of the catabolic state of prolonged critical illness
12/14/2000WO2000074698A1 Eugenia jambolina fruit extracts for treating diabetes
12/14/2000WO2000074684A1 Pharmaceutical formulations for treating postmenopausal and perimenopausal women, and their use
12/14/2000WO2000074666A2 Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidaemia and hyperuricaemia
12/14/2000WO2000074651A1 Pharmaceutical composition for intranasal use of active substances that are insoluble and/or hardly soluble in water
12/14/2000WO2000074650A2 Implantable gel compositions and method of manufacture
12/14/2000WO2000046225A3 Pyridobenzodiazepine and pyridobenzoxazepine carboxyamide vasopressin agonists
12/14/2000CA2751187A1 Use of (-)(3-trihalomethylphenoxy)(4-halophenyl)acetic acid and derivatives thereof for treatment of hyperuricemia
12/14/2000CA2376506A1 Neuromedin b and somatostatin receptor agonists
12/14/2000CA2376210A1 Therapeutic use of an inhibitor of a hedgehog or a hedgehog-related signalling pathway
12/14/2000CA2375914A1 Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same
12/14/2000CA2375912A1 Immunotherapy of autoimmune disorders using antibodies which target b-cells
12/14/2000CA2375734A1 Benzothiazinone and benzoxazinone compounds
12/14/2000CA2375148A1 Compositions for the treatment of the catabolic state of prolonged critical illness
12/13/2000EP1058726A2 Novel mechanically sensitive mammal potassium channel family activated by polyunsaturated fatty acids and their use particularly for screening medicines
12/12/2000US6159960 Steroid sulphatase inhibitors
12/07/2000WO2000073507A2 Identification of a novel retrovirus associated with primary biliary cirrhosis and autoimmune disorders
12/07/2000WO2000073450A2 Cytoskeleton-associated proteins
12/07/2000WO2000073449A1 Dna encoding snorf33 receptor
12/07/2000WO2000073443A1 Lipid metabolism transcription factor
12/07/2000WO2000073324A2 Modulation of gene expression in gastrointestinal inflammation
12/07/2000WO2000073292A1 Biaryl compounds
12/07/2000WO2000072920A1 Substituted biaryl ether compounds
12/07/2000WO2000072830A1 Method of producing submicron particles of a labile agent
12/07/2000WO2000072815A1 Indole derivatives
12/07/2000WO2000050456A3 Covalently bridged insulin dimers
12/07/2000WO2000049937A3 Trpm-2 antisense therapy
12/07/2000WO2000045790A3 Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
12/07/2000CA2375855A1 Modulation of gene expression in gastrointestinal inflammation
12/07/2000CA2375822A1 Substituted biaryl ether compounds
12/07/2000CA2375674A1 Biaryl compounds
12/07/2000CA2375147A1 Identification of a novel retrovirus associated with primary biliary cirrhosis and autoimmune disorders
12/07/2000CA2375047A1 Dna encoding snorf33 receptor
12/07/2000CA2374376A1 Lipid metabolism transcription factor
12/07/2000CA2374222A1 Cytoskeleton-associated proteins
1 ... 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 ... 290